These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 18716777

  • 1. Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial.
    Loibl S, Murmann C, Schwedler K, Warm M, Müller L, Heinrich G, Nekljudova V, von Minckwitz G.
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):953-8. PubMed ID: 18716777
    [Abstract] [Full Text] [Related]

  • 2. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
    Hsu C, Huang CS, Chao TY, Lu YS, Bu CF, Chen MM, Chang KJ, Cheng AL.
    Cancer; 2002 Nov 15; 95(10):2044-50. PubMed ID: 12412156
    [Abstract] [Full Text] [Related]

  • 3. Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy.
    Lalisang RI, Erdkamp FL, Rodenburg CJ, Knibbeler-van Rossum CT, Nortier JW, van Bochove A, Slee PH, Voest EE, Wils JA, Wals J, Loosveld OJ, Smals AE, Blijham GH, Tjan-Heijnen VC, Schouten HC.
    Breast Cancer Res Treat; 2011 Jul 15; 128(2):437-45. PubMed ID: 21584666
    [Abstract] [Full Text] [Related]

  • 4. Feasibility and therapeutic efficacy of weekly 1-h low-dose paclitaxel infusion for relapsed breast cancer.
    Kim R, Osaki A, Toge T.
    Oncol Rep; 2003 Jul 15; 10(1):145-50. PubMed ID: 12469161
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer.
    Lin CC, Cheng AL, Hsu CH, Lu YS, Hsu C, Yeh KH, Wu CY, Huang CS, Yang CH.
    Anticancer Res; 2007 Jul 15; 27(1B):641-5. PubMed ID: 17348454
    [Abstract] [Full Text] [Related]

  • 9. Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer: results of a clinical phase II study.
    Köhler U, Olbricht SS, Fuechsel G, Kettner E, Richter B, Ridwelski K.
    Semin Oncol; 1997 Oct 15; 24(5 Suppl 17):S17-40-S17-43. PubMed ID: 9374091
    [Abstract] [Full Text] [Related]

  • 10. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
    Eisen T, Thatcher N, Leyvraz S, Miller WH, Couture F, Lorigan P, Lüthi F, Small D, Tanovic A, O'Brien M.
    Lung Cancer; 2009 Apr 15; 64(1):60-5. PubMed ID: 18692272
    [Abstract] [Full Text] [Related]

  • 11. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
    O'connor T, Rustum Y, Levine E, Creaven P.
    Cancer Chemother Pharmacol; 2008 Jan 15; 61(1):125-31. PubMed ID: 17426973
    [Abstract] [Full Text] [Related]

  • 12. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.
    Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY.
    J Clin Oncol; 2008 Nov 10; 26(32):5269-74. PubMed ID: 18809609
    [Abstract] [Full Text] [Related]

  • 13. Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma.
    Gong Y, Ren L, Zhou L, Zhu J, Huang M, Zhou X, Wang J, Lu Y, Hou M, Wei Y.
    Cancer Chemother Pharmacol; 2009 Jul 10; 64(2):327-33. PubMed ID: 19048253
    [Abstract] [Full Text] [Related]

  • 14. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.
    Schrama JG, Baars JW, Holtkamp MJ, Schornagel JH, Beijnen JH, Rodenhuis S.
    Bone Marrow Transplant; 2001 Jul 10; 28(2):173-80. PubMed ID: 11509935
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group study.
    McMeekin DS, Walker JL, Hartenbach EM, Bookman MA, Koh WJ, Gynecologic Oncology Group.
    Gynecol Oncol; 2009 Jan 10; 112(1):134-41. PubMed ID: 18962846
    [Abstract] [Full Text] [Related]

  • 17. Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.
    Mita M, Mita A, Sarantopoulos J, Takimoto CH, Rowinsky EK, Romero O, Angiuli P, Allievi C, Eisenfeld A, Verschraegen CF.
    Cancer Chemother Pharmacol; 2009 Jul 10; 64(2):287-95. PubMed ID: 19034451
    [Abstract] [Full Text] [Related]

  • 18. [Weekly paclitaxel therapy for metastatic breast cancer].
    Kokufu I, Taniguchi H, Kimura F, Fukuda K, Yamamoto M, Yano T, Yamada K.
    Gan To Kagaku Ryoho; 2002 Feb 10; 29(2):221-6. PubMed ID: 11865627
    [Abstract] [Full Text] [Related]

  • 19. Phase I study of combination therapy with weekly paclitaxel and cyclophosphamide for advanced or recurrent breast cancer.
    Masuda N, Nakayama T, Yamamura J, Kamigaki S, Taguchi T, Hatta M, Sakamoto J.
    Cancer Chemother Pharmacol; 2010 May 10; 66(1):89-94. PubMed ID: 19768460
    [Abstract] [Full Text] [Related]

  • 20. Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study.
    Nisticò C, Bria E, Cuppone F, Fornier M, Sperduti I, Carpino A, Pace A, Cognetti F, Terzoli E.
    Anticancer Drugs; 2007 Jul 10; 18(6):687-92. PubMed ID: 17762397
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.